Share on StockTwits

Analysts at JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences Corp (NYSE:EW) from $78.00 to $90.00 in a research report issued to clients and investors on Thursday. JPMorgan Chase & Co.’s price target indicates a potential downside of 2.14% from the stock’s previous close.

EW has been the subject of a number of other recent research reports. Analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Separately, analysts at BMO Capital Markets raised their price target on shares of Edwards Lifesciences Corp from $84.00 to $89.00 in a research note on Thursday. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday. They now have a $90.00 price target on the stock, up previously from $81.00. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $90.00.

Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% during mid-day trading on Thursday, hitting $91.97. 1,899,876 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a 52-week low of $60.62 and a 52-week high of $94.50. The stock’s 50-day moving average is $85.98 and its 200-day moving average is $77.78. The company has a market cap of $9.712 billion and a P/E ratio of 13.02.

Edwards Lifesciences Corp (NYSE:EW) last released its earnings data on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.28 EPS for the current fiscal year.

In other Edwards Lifesciences Corp news, VP Patrick B. Verguet sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $92.00, for a total value of $460,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.